STOCKHOLM, November 11, 2026. In accordance with the Nomination Committee instructions adopted by the Annual General Meeting, the Chairman of the Board has contacted the company's largest shareholders at the end of Q3 2026, and each shareholder was offered to appoint a member to the company's Nomination Committee for the Annual General Meeting for the financial year January - December 2026. Three of the four largest shareholders or shareholder groups have agreed to form the Nomination Committee together with the Chairman of the company's Board of Directors.
STOCKHOLM, November 11, 2026. In accordance with the Nomination Committee instructions adopted by the Annual General Meeting, the Chairman of the Board has contacted the company's largest shareholders at the end of Q3 2026, and each shareholder was offered to appoint a member to the company's Nomination Committee for the Annual General Meeting for the financial year January - December 2026. Three of the four largest shareholders or shareholder groups have agreed to form the Nomination Committee together with the Chairman of the company's Board of Directors.
OncoZenge's Nomination Committee for the Annual General Meeting for the financial year January - December 2026 consists of:
- Xiang Yang (Austin), appointed by Sichuan Yangtian Bio-Pharmaceutical Co., Ltd.- Jan Poulsen, CEO of Life Science Invest Fund (LSIF), appointed by Andreas Özbek- Niclas Holmgren- Daniel Ehrenstråhle, Chairman of the Board
The Nomination Committee collectively represents approximately 33 percent of the voting rights of all shares in the company as of September 30, 2026.
The Nomination Committee's task is to present proposals to the Annual General Meeting for the financial year January - December 2026 regarding the election of the Chairman of the Board and other members of the Board, Board fees and other remuneration to the Board members, as well as election and remuneration of auditors.
The Annual General Meeting for the financial year January - December 2026 will be held on May 26, 2027. Shareholders who wish to submit proposals to OncoZenge's Nomination Committee can do so by e-mail to info@oncozenge.se no later than April 7, 2027.
BupiZenge™ - Potential to be the leading treatment for oral pain.
ContactsStian Kildal CEO Mobile: +46 76 115 3797 E-mail: stian.kildal@oncozenge.seDaniel Ehrenstråhle Chairman of the Board E-mail: daniel.ehrenstrahle@oncozenge.se
AboutOncoZenge AB (publ) is a clinical-stage pharmaceutical company developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options are insufficient, such as oral mucositis from cancer therapy. Its lead candidate, BupiZenge™, represents a novel formulation of bupivacaine in a lozenge form, aimed at providing rapid and sustained local pain relief without the risks associated with systemic opioids. The Company recently received European regulatory approval to initiate its pivotal Phase III study ‘BEAM-Pain’. The first patient has been enrolled in the trial and site activations are currently ongoing. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. For more information, please visit www.oncozenge.se.
OncoZenge ABGustavslundsvägen 34, 167 51 Stockholm, Sweden
Certified AdviserRedeye Nordic Growth AB is the company’s Certified Adviser.
AttachmentsNomination Committee appointed in OncoZenge AB